Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2201898 | PMC |
Publication Analysis
Top Keywords
Similar Publications
A Path Analysis Study on the Influence of Social Norms on Substance Use Severity: Focusing on People Who Use Cannabis, Narcotics, and Psychotropic Substances in South Korea.
Int J Environ Res Public Health
December 2024
Suicide Action Forum, Seoul 07214, Republic of Korea.
This study investigates the effects of social norms on substance use severity mediated by health beliefs among people who use cannabis, narcotics, and psychotropic substances in Republic of Korea. A survey was administered to 109 people who use cannabis and narcotics and 191 people who use psychotropic substances between May and July 2024. Path analysis was conducted.
View Article and Find Full Text PDFDevelopment and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose.
Nat Commun
January 2025
Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA, US.
The opioid crisis, driven by synthetic opioids like fentanyl, demands innovative solutions. The opioid antidote naloxone has a short action ( ~ 1 hour), requiring repeated doses. To address this, we present a new and simple naloxone prodrug delivery system repurposing a hydrophilic derivative of acoramidis, a potent transthyretin ligand.
View Article and Find Full Text PDFEffects of psychedelics on opioid use disorder: a scoping review of preclinical studies.
Cell Mol Life Sci
January 2025
Department of Psychiatry, Yale University School of Medicine, 300 George Street, Suite 901, New Haven, CT, 06511, USA.
The current opioid crisis has had an unprecedented public health impact. Approved medications for opioid use disorder (OUD) exist, yet their limitations indicate a need for innovative treatments. Limited preliminary clinical studies suggest specific psychedelics might aid OUD treatment, though most clinical evidence remains observational, with few controlled trials.
View Article and Find Full Text PDFPrevention of sufentanil-induced cough during induction of general anesthesia by low-dose esketamine.
BMC Anesthesiol
January 2025
Department of Anesthesiology, Air Force Medical Center, No.30 Fucheng Road, Haidian District, Beijing, 100142, China.
Background: Sufentanil is commonly used to induce general anaesthesia due to its rapid onset of action, strong analgesic effect, long-lasting effect, and stable haemodynamics; however, it often induces cough, increasing the risk of anaesthesia. This study aimed to investigate the preventive effect of low-dose esketamine on sufentanil-induced cough.
Methods: This randomised, double-blind, placebo-controlled clinical study was conducted at the Air Force Medical Center between September 2023 and May 2024.
Use of Causal Framework to Evaluate Effect of Abuse Deterrent Properties of Extended-Release Oxycodone on Tampering in a Real-World Settings.
Pharmacoepidemiol Drug Saf
January 2025
Rocky Mountain Poison & Drug Safety, Denver Health & Hospital Authority, Denver, Colorado, USA.
Purpose: To assess whether exposure to an extended-release (ER) oxycodone with abuse deterrent properties (ADF) reduced tampering of oxycodone in a real-world, postmarket setting to address the thinking behind Category 4 labeling by the FDA.
Methods: Data from an observational cross-sectional study of the general adult population (2022) was used under a causal framework to estimate the confounding-adjusted odds of tampering oxycodone after exposure to two types of ADF ER oxycodone. The tampering behaviors of those who used only single entity immediate-release (SE-IR) oxycodone was used as a comparison.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!